1
|
Dalton KP, Alvarado C, Reytor E, del Carmen Nuñez M, Podadera A, Martínez-Alonso D, Alonso JMM, Nicieza I, Gómez-Sebastián S, Dalton RM, Parra F, Escribano JM. Chimeric VLPs Bearing VP60 from Two Serotypes of Rabbit Haemorrhagic Disease Virus Are Protective against Both Viruses. Vaccines (Basel) 2021; 9:vaccines9091005. [PMID: 34579243 PMCID: PMC8472679 DOI: 10.3390/vaccines9091005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 08/26/2021] [Accepted: 08/31/2021] [Indexed: 11/24/2022] Open
Abstract
The VP60 capsid protein from rabbit haemorrhagic disease virus (RHDV), the causative agent of one of the most economically important disease in rabbits worldwide, forms virus-like particles (VLPs) when expressed using heterologous protein expression systems such as recombinant baculovirus, yeasts, plants or mammalian cell cultures. To prevent RHDV dissemination, it would be beneficial to develop a bivalent vaccine including both RHDV GI.1- and RHDV GI.2-derived VLPs to achieve robust immunisation against both serotypes. In the present work, we developed a strategy of production of a dual-serving RHDV vaccine co-expressing the VP60 proteins from the two RHDV predominant serotypes using CrisBio technology, which uses Tricholusia ni insect pupae as natural bioreactors, which are programmed by recombinant baculovirus vectors. Co-infecting the insect pupae with two baculovirus vectors expressing the RHDV GI.1- and RHDV GI.2-derived VP60 proteins, we obtained chimeric VLPs incorporating both proteins as determined by using serotype-specific monoclonal antibodies. The resulting VLPs showed the typical size and shape of this calicivirus as determined by electron microscopy. Rabbits immunised with the chimeric VLPs were fully protected against a lethal challenge infection with the two RHDV serotypes. This study demonstrates that it is possible to generate a dual cost-effective vaccine against this virus using a single production and purification process, greatly simplifying vaccine manufacturing.
Collapse
Affiliation(s)
- Kevin P. Dalton
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Carmen Alvarado
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Edel Reytor
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Maria del Carmen Nuñez
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Ana Podadera
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Diego Martínez-Alonso
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Jose Manuel Martin Alonso
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Ines Nicieza
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - Silvia Gómez-Sebastián
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Romy M. Dalton
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
| | - Francisco Parra
- Instituto Universitario de Biotecnología de Asturias, Departamento de Bioquímica y Biología Molecular, Campus El Cristo, Universidad de Oviedo, Edificio Santiago Gascón, 33006 Oviedo, Spain; (K.P.D.); (A.P.); (J.M.M.A.); (I.N.); (F.P.)
| | - José M. Escribano
- Alternative Gene Expression S.L. Ronda de Poniente 14, Tres Cantos, 28760 Madrid, Spain; (C.A.); (E.R.); (M.d.C.N.); (D.M.-A.); (S.G.-S.); (R.M.D.)
- Correspondence:
| |
Collapse
|
2
|
Kappler-Gratias S, Bucher L, Top S, Quentin-Froignant C, Desbois N, Bertagnoli S, Louison M, Monge E, Bousquet-Melou A, Lacroix M, Gros CP, Gallardo F. Antipoxvirus Activity Evaluation of Optimized Corroles Based on Development of Autofluorescent ANCHOR Myxoma Virus. ACS Infect Dis 2021; 7:2370-2382. [PMID: 34048219 DOI: 10.1021/acsinfecdis.1c00068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A series of 43 antiviral corrole-based molecules have been tested on myxoma virus (Lausanne-like T1MYXV strain). An autofluorescent MYXV, with an ANCHOR cassette, has been used for the studies. A2B-fluorocorroles display various toxicities, from 40 being very toxic (CC50 = 1.7 μM) to nontoxic 38 (CC50 > 50 μM), whereas A3-fluorocorroles, with one to three fluorine atoms, are not toxic (with the exception of corroles 9, 10, and 22). In vitro, these compounds show a good selectivity index when used alone. Corrole 35 seems to be the most promising compound, which displays a high selectivity index with the lowest IC50. Interestingly, this "Hit" corrole is easy to synthesize in a two-step reaction. Upscaling production up to 25 g has been carried out for in vivo tests. In vivo studies on New Zealand white rabbits infected with myxoma virus show that symptoms are delayed and animal weight is increased upon treatment, while no acute toxicity of the corrole molecule was detected.
Collapse
Affiliation(s)
| | - Léo Bucher
- Institut de Chimie Moléculaire de l’Université de Bourgogne (ICMUB, UMR CNRS 6302), Université Bourgogne Franche-Comté, 9 avenue Alain Savary, BP 47870, 21078 Dijon Cedex, France
| | - Sokunthea Top
- NeoVirTech, SAS, 1 place Pierre Potier, Oncopole, 31106 Toulouse, France
- IHAP, Université de Toulouse, INRAE, ENVT, 31076 Toulouse Cedex 3, France
| | - Charlotte Quentin-Froignant
- NeoVirTech, SAS, 1 place Pierre Potier, Oncopole, 31106 Toulouse, France
- IHAP, Université de Toulouse, INRAE, ENVT, 31076 Toulouse Cedex 3, France
| | - Nicolas Desbois
- Institut de Chimie Moléculaire de l’Université de Bourgogne (ICMUB, UMR CNRS 6302), Université Bourgogne Franche-Comté, 9 avenue Alain Savary, BP 47870, 21078 Dijon Cedex, France
| | | | - Matthieu Louison
- IHAP, Université de Toulouse, INRAE, ENVT, 31076 Toulouse Cedex 3, France
| | - Emma Monge
- IHAP, Université de Toulouse, INRAE, ENVT, 31076 Toulouse Cedex 3, France
| | | | - Marlène Lacroix
- INTHERES, Université de Toulouse, INRAE, ENVT, 31076 Toulouse Cedex 3, France
| | - Claude P. Gros
- Institut de Chimie Moléculaire de l’Université de Bourgogne (ICMUB, UMR CNRS 6302), Université Bourgogne Franche-Comté, 9 avenue Alain Savary, BP 47870, 21078 Dijon Cedex, France
| | - Franck Gallardo
- NeoVirTech, SAS, 1 place Pierre Potier, Oncopole, 31106 Toulouse, France
| |
Collapse
|
3
|
Müller C, Hrynkiewicz R, Bębnowska D, Maldonado J, Baratelli M, Köllner B, Niedźwiedzka-Rystwej P. Immunity against Lagovirus europaeus and the Impact of the Immunological Studies on Vaccination. Vaccines (Basel) 2021; 9:vaccines9030255. [PMID: 33805607 PMCID: PMC8002203 DOI: 10.3390/vaccines9030255] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 03/08/2021] [Accepted: 03/09/2021] [Indexed: 12/14/2022] Open
Abstract
In the early 1980s, a highly contagious viral hemorrhagic fever in rabbits (Oryctolagus cuniculus) emerged, causing a very high rate of mortality in these animals. Since the initial occurrence of the rabbit hemorrhagic disease virus (RHDV), several hundred million rabbits have died after infection. The emergence of genetically-different virus variants (RHDV GI.1 and GI.2) indicated the very high variability of RHDV. Moreover, with these variants, the host range broadened to hare species (Lepus). The circulation of RHDV genotypes displays different virulences and a limited induction of cross-protective immunity. Interestingly, juvenile rabbits (<9 weeks of age) with an immature immune system display a general resistance to RHDV GI.1, and a limited resistance to RHDV GI.2 strains, whereas less than 3% of adult rabbits survive an infection by either RHDV GI.1. or GI.2. Several not-yet fully understood phenomena characterize the RHD. A very low infection dose followed by an extremely rapid viral replication could be simplified to the induction of a disseminated intravascular coagulopathy (DIC), a severe loss of lymphocytes—especially T-cells—and death within 36 to 72 h post infection. On the other hand, in animals surviving the infection or after vaccination, very high titers of RHDV-neutralizing antibodies were induced. Several studies have been conducted in order to deepen the knowledge about the virus’ genetics, epidemiology, RHDV-induced pathology, and the anti-RHDV immune responses of rabbits in order to understand the phenomenon of the juvenile resistance to this virus. Moreover, several approaches have been used to produce efficient vaccines in order to prevent an infection with RHDV. In this review, we discuss the current knowledge about anti-RHDV resistance and immunity, RHDV vaccination, and the further need to establish rationally-based RHDV vaccines.
Collapse
Affiliation(s)
- Claudia Müller
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institute, 17493 Greifswald-Insel Riems, Germany;
| | - Rafał Hrynkiewicz
- Institute of Biology, University of Szczecin, Felczaka 3c, 71-412 Szczecin, Poland; (R.H.); (D.B.)
| | - Dominika Bębnowska
- Institute of Biology, University of Szczecin, Felczaka 3c, 71-412 Szczecin, Poland; (R.H.); (D.B.)
| | | | | | - Bernd Köllner
- Institute of Immunology, Friedrich-Loeffler-Institute, 17493 Greifswald-Insel Riems, Germany
- Correspondence: (B.K.); (P.N.-R.)
| | - Paulina Niedźwiedzka-Rystwej
- Institute of Biology, University of Szczecin, Felczaka 3c, 71-412 Szczecin, Poland; (R.H.); (D.B.)
- Correspondence: (B.K.); (P.N.-R.)
| |
Collapse
|
4
|
Strict Assembly Restriction of Peptides from Rabbit Hemorrhagic Disease Virus Presented by Rabbit Major Histocompatibility Complex Class I Molecule RLA-A1. J Virol 2020; 94:JVI.00396-20. [PMID: 32522857 DOI: 10.1128/jvi.00396-20] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Accepted: 06/02/2020] [Indexed: 12/28/2022] Open
Abstract
Rabbits are pivotal domestic animals for both the economy and as an animal model for human diseases. A large number of rabbits have been infected by rabbit hemorrhagic disease virus (RHDV) in natural and artificial pandemics in the past. Differences in presentation of antigenic peptides by polymorphic major histocompatibility complex (MHC) molecules to T-cell receptors (TCR) on T lymphocytes are associated with viral clearance in mammals. Here, we screened and identified a series of peptides derived from RHDV binding to the rabbit MHC class I molecule, RLA-A1. The small, hydrophobic B and F pockets of RLA-A1 capture a peptide motif analogous to that recognized by human class I molecule HLA-A*0201, with more restricted aliphatic anchors at P2 and PΩ positions. Moreover, the rabbit molecule is characterized by an uncommon residue combination of Gly53, Val55, and Glu56, making the 310 helix and the loop between the 310 and α1 helices closer to the α2 helix. A wider A pocket in RLA-A1 can induce a special conformation of the P1 anchor and may play a pivotal role in peptide assembly and TCR recognition. Our study broadens the knowledge of T-cell immunity in domestic animals and also provides useful insights for vaccine development to prevent infectious diseases in rabbits.IMPORTANCE We screened rabbit MHC class I RLA-A1-restricted peptides from the capsid protein VP60 of rabbit hemorrhagic disease virus (RHDV) and determined the structures of RLA-A1 complexed with three peptides, VP60-1, VP60-2, and VP60-10. From the structures, we found that the peptide binding motifs of RLA-A1 are extremely constraining. Thus, there is a generally restricted peptide selection for RLA-A1 compared to that for human HLA-A*0201. In addition, uncommon residues Gly53, Val55, and Glu56 of RLA-A1 are located between the 310 helix and α1 helix, which makes the steric position of the 310 helix in RLA-A1 much closer to the α2 helix than that found in other mammalian MHC class I molecules. This special conformation between the 310 helix and α1 helix plays a pivotal role in rabbit MHC class I assembly. Our results provide new insights into MHC class I molecule assembly and peptide presentation of domestic mammals. Furthermore, these data also broaden our knowledge on T-cell immunity in rabbits and may also provide useful information for vaccine development to prevent infectious diseases in rabbits.
Collapse
|
5
|
Müller C, Ulrich R, Franzke K, Müller M, Köllner B. Crude extracts of recombinant baculovirus expressing rabbit hemorrhagic disease virus 2 VLPs from both insect and rabbit cells protect rabbits from rabbit hemorrhagic disease caused by RHDV2. Arch Virol 2018; 164:137-148. [PMID: 30291504 DOI: 10.1007/s00705-018-4032-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 07/14/2018] [Indexed: 12/19/2022]
Abstract
Vaccines against viral pathogens are often composed of recombinant proteins expressed in different systems. Such proteins expressed by recombinant baculoviruses have been proven to be effective for vaccination. Especially, after codon usage optimization high amounts of recombinant viral proteins can be obtained which can assemble to virus like particles (VLPs) spontaneously. In this study we compared two different codon usages of RHDV2-VP1 to improve the expression of recombinant VP1 of RHDV2 by recombinant baculoviruses after infection of insect SF9 cells or transduction of mammalian RK13 cells in order to gain high protein yields. Also the influence on the auto-assembly of RHDV2-VP1 to VLPs was investigated. Finally, the immunogenic potential of such recombinant vaccines against RHDV2 to induce a protective immune response in rabbits against RHDV2 should be characterized. There was no influence of different codon usages on RHDV2-VP1 gene expression in the respective cell lines detected. However, in insect cell line SF9 higher rates of recombinant VP1 were measured in comparison to the transduction of mammalian cells RK13. Auto-assembly of RHDV2-VP1 to VLPs was observed in both cell systems by electron microscopy. Finally, both RHDV-VP1 VLPs derived from mammalian and insect cells were able to induce a protective humoral immune response in rabbits against RHDV2.
Collapse
Affiliation(s)
- Claudia Müller
- Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany
| | - Reiner Ulrich
- Department of Experimental Animal Facilities and Biorisk Management, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany
| | - Kati Franzke
- Institute of Infectology, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany
| | - Marcus Müller
- IDT Biologika (Riems), Greifswald-Insel Riems, Germany
| | - Bernd Köllner
- Institute of Immunology, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany.
| |
Collapse
|
6
|
Manev I, Genova K, Lavazza A, Capucci L. Humoral immune response to different routes of myxomatosis vaccine application. WORLD RABBIT SCIENCE 2018. [DOI: 10.4995/wrs.2018.7021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The aim of our study was to monitor the dynamics of the serological response to different application routes of live attenuated myxomatosis vaccine. The study included 42 Californian breed rabbits, aged 3 mo, of both sexes. They were separated into 7 groups: 6 experimental and 1 control. All experimental groups were vaccinated on day 0 with a single dose of myxomatosis vaccine (min 10<sup>3.3</sup> tissue culture infective dose 50 [TCID<sub>50</sub>], max 10<sup>5.8</sup> TCID<sub>50</sub>). Three of the groups were injected with monovalent attenuated myxomatosis vaccine using different types of application: intradermal (i.d.), intramuscular (i.m.) and subcutaneous (s.c.). The other 3 groups were injected with bivalent attenuated vaccine against myxomatosis and rabbit haemorrhagic disease; again the routes of administration were i.d., i.m. and s.c.. There were no clinical signs or serious side effects after vaccination. The serological response was evaluated on days 7, 15 and 30 with a monoclonal antibody based-competition enzyme-linked immunosorbent assay (cELISA). More rapid and potent humoral response was detected in groups with i.d. inoculation in comparison to i.m. and s.c. routes. Vaccination with monovalent vaccine against myxomatosis induced higher antibody titre in comparison to bivalent vaccine. Our study showed that the vaccine application route and the type of vaccine used influence the speed and intensity of antibody response.
Collapse
|
7
|
Guo H, Zhu J, Tan Y, Li C, Chen Z, Sun S, Liu G. Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits. Antiviral Res 2016; 131:85-91. [PMID: 27118636 DOI: 10.1016/j.antiviral.2016.04.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 04/09/2016] [Accepted: 04/18/2016] [Indexed: 12/23/2022]
Abstract
In this study, virus-like particles (VLPs) derived from rabbit hemorrhagic disease virus (RHDV) were evaluated for the development of a vaccine against RHDV infection. The VP60 gene was cloned and inserted into a pSMK expression vector containing a small ubiquitin-like modifier (SUMO) tag that can promote the soluble expression of heterologous proteins in Escherichia coli cells. After expression and purification of His-SUMO-VP60 and cleavage of the SUMO tag, we found that the RHDV VP60 protein had self-assembled into VLPs with a similar shape and smaller size compared with authentic RHDV capsid. Next, the antigenicity and immunogenicity of the VLPs were examined. The results showed that RHDV-specific responses were clearly induced in rabbits and that all rabbits in the VLP group survived while those in the negative control group died within 72 h post-infection. These results suggest that VLP-based RHDV could be a promising RHDV vaccine candidate.
Collapse
Affiliation(s)
- Huimin Guo
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China
| | - Jie Zhu
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China
| | - Yonggui Tan
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China
| | - Chuanfeng Li
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China
| | - Zongyan Chen
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China
| | - Shiqi Sun
- Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 730046, Gansu, China.
| | - Guangqing Liu
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai, China.
| |
Collapse
|
8
|
Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. The evolution of poxvirus vaccines. Viruses 2015; 7:1726-803. [PMID: 25853483 PMCID: PMC4411676 DOI: 10.3390/v7041726] [Citation(s) in RCA: 133] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 03/16/2015] [Accepted: 03/27/2015] [Indexed: 02/07/2023] Open
Abstract
After Edward Jenner established human vaccination over 200 years ago, attenuated poxviruses became key players to contain the deadliest virus of its own family: Variola virus (VARV), the causative agent of smallpox. Cowpox virus (CPXV) and horsepox virus (HSPV) were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia virus (VACV), which was used in the final campaigns aimed to eradicate the disease, an endeavor that was accomplished by the World Health Organization (WHO) in 1980. Ever since, naturally evolved strains used for vaccination were introduced into research laboratories where VACV and other poxviruses with improved safety profiles were generated. Recombinant DNA technology along with the DNA genome features of this virus family allowed the generation of vaccines against heterologous diseases, and the specific insertion and deletion of poxvirus genes generated an even broader spectrum of modified viruses with new properties that increase their immunogenicity and safety profile as vaccine vectors. In this review, we highlight the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.
Collapse
MESH Headings
- Animals
- History, 18th Century
- History, 19th Century
- History, 20th Century
- History, 21st Century
- Humans
- Poxviridae/immunology
- Poxviridae/isolation & purification
- Smallpox/prevention & control
- Smallpox Vaccine/history
- Smallpox Vaccine/immunology
- Smallpox Vaccine/isolation & purification
- Vaccines, Attenuated/history
- Vaccines, Attenuated/immunology
- Vaccines, Attenuated/isolation & purification
- Vaccines, Synthetic/history
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/isolation & purification
Collapse
Affiliation(s)
- Lucas Sánchez-Sampedro
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain.
| | - Beatriz Perdiguero
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain.
| | - Ernesto Mejías-Pérez
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain
| | - Juan García-Arriaza
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain
| | - Mauro Di Pilato
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain.
| | - Mariano Esteban
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid-28049, Spain.
| |
Collapse
|
9
|
Li ZX, Hu WD, Li BC, Li TY, Zhou XY, Zhang Z. Egg yolk IgY against RHDV capsid protein VP60 promotes rabbit defense against RHDV infection. Vet Immunol Immunopathol 2013; 157:97-104. [PMID: 24252247 DOI: 10.1016/j.vetimm.2013.10.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 09/26/2013] [Accepted: 10/08/2013] [Indexed: 01/14/2023]
Abstract
VP60 capsid protein is the major structural and immunogenicity protein of RHDV (Rabbit hemorrhagic disease virus, RHDV), and has been implicated as a main protein antigen in RHDV diagnosis and vaccine design. In this report, egg yolk antibody (IgY) against N-terminal of VP60 was evaluated and developed as a new strategy for RHDV therapy. Briefly, N-terminal of VP60 (∼250aa) fragment was cloned and inserted into pET28a expression vector, and then the resultant plasmid, pET28a/VP60-N, was transformed into E. coli BL21(DE3) for recombinant VP60-N protein (rVP60-N) expression. Next, the rVP60-N was purified by Ni(+)-affinity purification chromatography and identified by Western blotting with RHDV antiserum. After immunizing the chickens with rVP60-N, the anti-rVP60-N IgY was isolated, and the activity and specificity of the IgY antibody were analyzed by ELISA and Western blotting. In our results, the rVP60-N could be expressed in E. coli as soluble fraction, and the isolated anti-rVP60-N IgY demonstrated a high specificity and titer (1:22,000) against rVP60-N antigen. For further evaluation of the IgY efficacy in vivo, rabbits were grouped randomly and challenged with RHDV, and the results showed that anti-rVP60-N IgY could significantly protect rabbits from virus infection and promote the host survival after a sustained treatment with anti-rVP60-N IgY for 5 days. Taken together, our study demonstrates evidence that production of IgY against VP60 could be as a novel strategy for the RHDV therapy.
Collapse
Affiliation(s)
- Zai Xin Li
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China
| | - Wei Dong Hu
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China
| | - Bing Chao Li
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China
| | - Tian You Li
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China
| | - Xiao Yang Zhou
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China
| | - Zhi Zhang
- Key Laboratory of Pharmaceutical Engineering Technology and Application, School of Chemical and Pharmaceutical Engineering, Sichuan University of Science and Engineering, Zigong 643000, China.
| |
Collapse
|
10
|
Gao J, Meng C, Chen Z, Li C, Liu G. Codon optimization of the rabbit hemorrhagic disease virus (RHDV) capsid gene leads to increased gene expression in Spodoptera frugiperda 9 (Sf9) cells. J Vet Sci 2013; 14:441-7. [PMID: 23820215 PMCID: PMC3885738 DOI: 10.4142/jvs.2013.14.4.441] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Accepted: 02/16/2013] [Indexed: 01/31/2023] Open
Abstract
Rabbit hemorrhagic disease (RHD) is contagious and highly lethal. Commercial vaccines against RHD are produced from the livers of experimentally infected rabbits. Although several groups have reported that recombinant subunit vaccines against rabbit hemorrhagic disease virus (RHDV) are promising, application of the vaccines has been restricted due to high production costs or low yield. In the present study, we performed codon optimization of the capsid gene to increase the number of preference codons and eliminate rare codons in Spodoptera frugiperda 9 (Sf9) cells. The capsid gene was then subcloned into the pFastBac plasmid, and the recombinant baculoviruses were identified with a plaque assay. As expected, expression of the optimized capsid protein was markedly increased in the Sf9 cells, and the recombinant capsid proteins self-assembled into virus-like particles (VLPs) that were released into the cell supernatant. Rabbits inoculated with the supernatant and the purified VLPs were protected against RHDV challenge. A rapid, specific antibody response against RHDV was detected by an ELISA in all of the experimental groups. In conclusion, this strategy of producing a recombinant subunit vaccine antigen can be used to develop a low-cost, insect cell-derived recombinant subunit vaccine against RHDV.
Collapse
Affiliation(s)
- Jingpeng Gao
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China
| | | | | | | | | |
Collapse
|
11
|
Cheng Y, Chen Z, Li C, Meng C, Wu R, Liu G. Protective immune responses in rabbits induced by a suicidal DNA vaccine of the VP60 gene of rabbit hemorrhagic disease virus. Antiviral Res 2013; 97:227-31. [DOI: 10.1016/j.antiviral.2012.12.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2012] [Revised: 12/14/2012] [Accepted: 12/15/2012] [Indexed: 11/29/2022]
|
12
|
Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine. PLoS One 2013; 8:e56417. [PMID: 23460801 PMCID: PMC3584067 DOI: 10.1371/journal.pone.0056417] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2012] [Accepted: 01/08/2013] [Indexed: 01/15/2023] Open
Abstract
Recombinant virus-like particles (VLP) antigenically similar to rabbit hemorrhagic disease virus (RHDV) were recently expressed at high levels inside Pichia pastoris cells. Based on the potential of RHDV VLP as platform for diverse vaccination purposes we undertook the design, development and scale-up of a production process. Conformational and stability issues were addressed to improve process control and optimization. Analyses on the structure, morphology and antigenicity of these multimers were carried out at different pH values during cell disruption and purification by size-exclusion chromatography. Process steps and environmental stresses in which aggregation or conformational instability can be detected were included. These analyses revealed higher stability and recoveries of properly assembled high-purity capsids at acidic and neutral pH in phosphate buffer. The use of stabilizers during long-term storage in solution showed that sucrose, sorbitol, trehalose and glycerol acted as useful aggregation-reducing agents. The VLP emulsified in an oil-based adjuvant were subjected to accelerated thermal stress treatments. None to slight variations were detected in the stability of formulations and in the structure of recovered capsids. A comprehensive analysis on scale-up strategies was accomplished and a nine steps large-scale production process was established. VLP produced after chromatographic separation protected rabbits against a lethal challenge. The minimum protective dose was identified. Stabilized particles were ultimately assayed as carriers of a foreign viral epitope from another pathogen affecting a larger animal species. For that purpose, a linear protective B-cell epitope from Classical Swine Fever Virus (CSFV) E2 envelope protein was chemically coupled to RHDV VLP. Conjugates were able to present the E2 peptide fragment for immune recognition and significantly enhanced the peptide-specific antibody response in vaccinated pigs. Overall these results allowed establishing improved conditions regarding conformational stability and recovery of these multimers for their production at large-scale and potential use on different animal species or humans.
Collapse
|
13
|
Qiu L, Wang X, Hao H, Mu G, Dang R, Wang J, Zhang S, Du E, Yang Z. Oral administration of attenuated Salmonella typhimurium containing a DNA vaccine against rabbit haemorrhagic disease. J Virol Methods 2012; 188:108-13. [PMID: 23270916 DOI: 10.1016/j.jviromet.2012.12.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2012] [Revised: 12/05/2012] [Accepted: 12/10/2012] [Indexed: 10/27/2022]
Abstract
The use of attenuated Salmonella typhimurium as a bactofection vehicle for the oral delivery of a DNA vaccine against rabbit haemorrhagic disease virus (RHDV) was investigated. The DNA vaccine plasmid pcDNA3.1-VP60, which encodes the viral capsid protein VP60, was transformed into the attenuated S. typhimurium strain SL7207. The resulting recombinant bacteria, named as SL/pcDNA3.1-VP60, were orally used to immunise rabbits. The successful delivery of the DNA plasmid was confirmed by the detected VP60 transcription in the rabbit intestines through the reverse transcription polymerase chain reaction. In addition, the RHDV-specific humoral and cell-mediated immune response that was induced by SL/pcDNA3.1-VP60 was detected by the enzyme-linked immunosorbent assay as well as the assays for T lymphocyte proliferation and cytokines secretion. The significant protection of immunised rabbits against the RHDV strain XA/China/2010 at 42 d post-immunisation was demonstrated. This study is the first report about the efficient usage of attenuated Salmonella as a live vector for the oral delivery of a DNA vaccine against RHDV.
Collapse
Affiliation(s)
- Li Qiu
- College of Veterinary Medicine, Northwest A&F University, Yangling 712100, China
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Abrantes J, van der Loo W, Le Pendu J, Esteves PJ. Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. Vet Res 2012; 43:12. [PMID: 22325049 PMCID: PMC3331820 DOI: 10.1186/1297-9716-43-12] [Citation(s) in RCA: 254] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2011] [Accepted: 02/10/2012] [Indexed: 02/06/2023] Open
Abstract
Rabbit haemorrhagic disease virus (RHDV) is a calicivirus of the genus Lagovirus that causes rabbit haemorrhagic disease (RHD) in adult European rabbits (Oryctolagus cuniculus). First described in China in 1984, the virus rapidly spread worldwide and is nowadays considered as endemic in several countries. In Australia and New Zealand where rabbits are pests, RHDV was purposely introduced for rabbit biocontrol. Factors that may have precipitated RHD emergence remain unclear, but non-pathogenic strains seem to pre-date the appearance of the pathogenic strains suggesting a key role for the comprehension of the virus origins. All pathogenic strains are classified within one single serotype, but two subtypes are recognised, RHDV and RHDVa. RHD causes high mortality in both domestic and wild adult animals, with individuals succumbing between 48-72 h post-infection. No other species has been reported to be fatally susceptible to RHD. The disease is characterised by acute necrotising hepatitis, but haemorrhages may also be found in other organs, in particular the lungs, heart, and kidneys due to disseminated intravascular coagulation. Resistance to the disease might be explained in part by genetically determined absence or weak expression of attachment factors, but humoral immunity is also important. Disease control in rabbitries relies mainly on vaccination and biosecurity measures. Such measures are difficult to be implemented in wild populations. More recent research has indicated that RHDV might be used as a molecular tool for therapeutic applications. Although the study of RHDV and RHD has been hampered by the lack of an appropriate cell culture system for the virus, several aspects of the replication, epizootology, epidemiology and evolution have been disclosed. This review provides a broad coverage and description of the current knowledge on the disease and the virus.
Collapse
Affiliation(s)
- Joana Abrantes
- CIBIO/UP, Centro de Investigacao em Biodiversidade e Recursos Geneticos/Universidade do Porto, Campus Agrario de Vairao, 4485-661 Vairao, Portugal
- INSERM, U892, Université de Nantes, 44007 Nantes, France
| | - Wessel van der Loo
- CIBIO/UP, Centro de Investigacao em Biodiversidade e Recursos Geneticos/Universidade do Porto, Campus Agrario de Vairao, 4485-661 Vairao, Portugal
| | | | - Pedro J Esteves
- CIBIO/UP, Centro de Investigacao em Biodiversidade e Recursos Geneticos/Universidade do Porto, Campus Agrario de Vairao, 4485-661 Vairao, Portugal
- CITS, Centro de Investigacao em Tecnologias de Saude, CESPU, Gandra, Portugal
| |
Collapse
|
15
|
Kerr PJ. Myxomatosis in Australia and Europe: a model for emerging infectious diseases. Antiviral Res 2012; 93:387-415. [PMID: 22333483 DOI: 10.1016/j.antiviral.2012.01.009] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2011] [Revised: 01/20/2012] [Accepted: 01/26/2012] [Indexed: 11/18/2022]
Abstract
Myxoma virus is a poxvirus naturally found in two American leporid (rabbit) species (Sylvilagus brasiliensis and Sylvilagus bachmani) in which it causes an innocuous localised cutaneous fibroma. However, in European rabbits (Oryctolagus cuniculus) the same virus causes the lethal disseminated disease myxomatosis. The introduction of myxoma virus into the European rabbit population in Australia in 1950 initiated the best known example of what happens when a novel pathogen jumps into a completely naïve new mammalian host species. The short generation time of the rabbit and their vast numbers in Australia meant evolution could be studied in real time. The carefully documented emergence of attenuated strains of virus that were more effectively transmitted by the mosquito vector and the subsequent selection of rabbits with genetic resistance to myxomatosis is the paradigm for pathogen virulence and host-pathogen coevolution. This natural experiment was repeated with the release of a separate strain of myxoma virus in France in 1952. The subsequent spread of the virus throughout Europe and its coevolution with the rabbit essentially paralleled what occurred in Australia. Detailed molecular studies on myxoma virus have dissected the role of virulence genes in the pathogenesis of myxomatosis and when combined with genomic data and reverse genetics should in future enable the understanding of the molecular evolution of the virus as it adapted to its new host. This review describes the natural history and evolution of myxoma virus together with the molecular biology and experimental pathogenesis studies that are informing our understanding of evolution of emerging diseases.
Collapse
Affiliation(s)
- Peter J Kerr
- CSIRO Ecosystem Sciences, GPO Box 1700, Canberra, ACT 2601, Australia.
| |
Collapse
|
16
|
|
17
|
Rohde J, Schirrmeier H, Granzow H, Rziha HJ. A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV). Vaccine 2011; 29:9256-64. [DOI: 10.1016/j.vaccine.2011.09.121] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 09/20/2011] [Accepted: 09/22/2011] [Indexed: 11/29/2022]
|
18
|
Zheng T, Parkes JP. Rabbit haemorrhagic disease: advantages of cELISA in assessing immunity in wild rabbits (Oryctolagus cuniculus). Vet Microbiol 2011; 153:387-92. [PMID: 21719216 DOI: 10.1016/j.vetmic.2011.05.049] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2011] [Revised: 05/26/2011] [Accepted: 05/31/2011] [Indexed: 11/30/2022]
Abstract
Rabbit haemorrhagic disease (RHD) is an acute fatal disease of domestic and wild European rabbits (Oryctolagus cuniculus) caused by RHD virus (RHDV). Accurate assessment of immunity is of great importance for the conservation and control of wild rabbits. We evaluated a competitive ELISA (cELISA) against isotype ELISAs for assessing the protective immunity against the disease by challenging 50 wild-caught rabbits with a lethal dose of RHDV. Death or survival to the challenge was used as a criterion to determine the performance characteristics of the assay for the assessment of immunity in rabbits. At 1:10 dilution, a serum exhibiting ≥ 25% inhibition (1:10(25)) was regarded as the presence of RHDV-specific antibodies. Eleven of 16 (68.8%) rabbits with antibodies at 1:10(25) (<1:40) died of RHD. When the cut-off was moved from 25% to 50% inhibition (1:10(50)) at 1:10 serum dilution, the assay sensitivity, specificity and accuracy for the protective immunity were improved from 84%, 54.2% and 69.4% to 84%, 100% and 91.8%, respectively. We also demonstrated at the epitope amino acid sequence level why the presence of the RHDV-cross reactive benign rabbit calicivirus, which interfered with isotype ELISAs, had little impact on the specificity of the cELISA for the diagnosis of RHDV infection. The presence of RHDV-specific antibody at 1:10(50) by the cELISA is a reliable indicator for the protective immunity. In contrast to isotype ELISAs, the cELISA is a valuable specific tool for monitoring the herd immunity to RHD for the conservation and management of wild rabbits in the field.
Collapse
Affiliation(s)
- Tao Zheng
- AgResearch Grasslands, Hopkirk Research Institute, Private Bag 11008, Palmerston North 4442, New Zealand.
| | | |
Collapse
|
19
|
Spiesschaert B, McFadden G, Hermans K, Nauwynck H, Van de Walle GR. The current status and future directions of myxoma virus, a master in immune evasion. Vet Res 2011; 42:76. [PMID: 21658227 PMCID: PMC3131250 DOI: 10.1186/1297-9716-42-76] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Accepted: 06/09/2011] [Indexed: 01/12/2023] Open
Abstract
Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century. Table of contents Abstract 1. The virus 2. History 3. Pathogenesis and disease symptoms 4. Immunomodulatory proteins of MYXV 4.1. MYXV proteins with anti-apoptotic functions 4.1.1. Inhibition of pro-apoptotic molecules 4.1.2. Inhibition by protein-protein interactions by ankyrin repeat viral proteins 4.1.3. Inhibition of apoptosis by enhancing the degradation of cellular proteins 4.1.4. Inhibition of apoptosis by blocking host Protein Kinase R (PKR) 4.2. MYXV proteins interfering with leukocyte chemotaxis 4.3. MYXV serpins that inhibit cellular pro-inflammatory or pro-apoptotic proteases 4.4. MYXV proteins that interfere with leukocyte activation 4.5. MYXV proteins with sequence similarity to HIV proteins 4.6. MYXV proteins with unknown immune function 5. Vaccination strategies against myxomatosis 5.1. Current MYXV vaccines 5.2. Vaccination campaigns to protect European rabbits in the wild 6. Applications of myxoma virus for human medicine 6.1. MYXV proteins as therapeutics for allograft vasculopathy and atherosclerosis 6.2. Applications for MYXV as a live oncolytic virus to treat cancer 7. Discussion and Conclusions 8. List of Abbreviations References Author Details Authors' contributions Competing interests Figure Legends Acknowledgements
Collapse
Affiliation(s)
- Bart Spiesschaert
- Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium.
| | | | | | | | | |
Collapse
|
20
|
Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration. Vet Immunol Immunopathol 2011; 142:179-88. [PMID: 21621855 DOI: 10.1016/j.vetimm.2011.05.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Revised: 04/14/2011] [Accepted: 05/03/2011] [Indexed: 11/24/2022]
Abstract
Rabbit hemorrhagic disease virus (RHDV) is the etiological agent of a lethal and contagious disease of rabbits that remains as a serious problem worldwide. As this virus does not replicate in cell culture systems, the capsid protein gene has been expressed in heterologous hosts or inserted in replication-competent viruses in order to obtain non-conventional RHDV vaccines. However, due to technological or safety issues, current RHDV vaccines are still prepared from organs of infected rabbits. In this work, two human type 5 derived replication-defective adenoviruses encoding the rabbit hemorrhagic disease virus VP60 capsid protein were constructed. The recombinant protein was expressed as a multimer in mouse and rabbit cell lines at levels that ranged from approximately 120 to 160 mg/L of culture. Mice intravenously or subcutaneously inoculated with a single 10(8) gene transfer units (GTU) dose of the AdVP60 vector (designed for VP60 intracellular expression) seroconverted at days 7 and 14 post-immunization, respectively. This vector generated a stronger response than that obtained with a second vector (AdVP60sec) designed for VP60 secretion. Rabbits were then immunized by parenteral or mucosal routes with a single 10(9)GTU dose of the AdVP60 and the antibody response was evaluated using a competition ELISA specific for RHDV or RHDVa. Protective hemagglutination inhibition (HI) titers were also promptly detected and IgG antibodies corresponding with inhibition percentages over 85% persisted up to one year in all rabbits, independently of the immunization route employed. These levels were similar to those elicited with inactivated RHDV or with VP60 obtained from yeast or insect cells. IgA specific antibodies were only found in saliva of rabbits immunized by intranasal instillation. The feasibility of VP60 production and vaccination of rabbits with replication-defective adenoviral vectors was demonstrated.
Collapse
|
21
|
Le Gall-Reculé G, Zwingelstein F, Fages MP, Bertagnoli S, Gelfi J, Aubineau J, Roobrouck A, Botti G, Lavazza A, Marchandeau S. Characterisation of a non-pathogenic and non-protective infectious rabbit lagovirus related to RHDV. Virology 2010; 410:395-402. [PMID: 21195443 DOI: 10.1016/j.virol.2010.12.001] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2010] [Revised: 10/03/2010] [Accepted: 12/03/2010] [Indexed: 11/17/2022]
Abstract
The existence of non-pathogenic RHDV strains was established when a non-lethal virus named rabbit calicivirus (RCV) was characterised in 1996 in Italy. Since then, different RNA sequences related to RHDV have been detected in apparently healthy domestic and wild rabbits, and recently a new lagovirus was identified in Australia. We have characterised from seropositive healthy domestic rabbits a non-lethal lagovirus that differs from RHDV in terms of pathogenicity, tissue tropism and capsid protein sequence. Phylogenetic analyses have revealed that it is close to the Ashington strain and to the RCV, but distinct. We proved experimentally that it is infectious but non-pathogenic and demonstrated that, contrary to the other described non-pathogenic lagoviruses, it induces antibodies that do not protect against RHDV. Our results indicate the existence of a gradient of cross-protection between circulating strains, from non-protective, partially protective to protective strains, and highlight the extent of diversity within the genus Lagovirus.
Collapse
Affiliation(s)
- Ghislaine Le Gall-Reculé
- French Agency for Food, Environmental and Occupational Health Safety (Anses), Laboratory for Studies and Research on Poultry, Pig and Fish Farming (LERAPP), UVIPAC, BP 53, F-22440 Ploufragan, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 2009; 26:6508-28. [PMID: 18838097 PMCID: PMC7131726 DOI: 10.1016/j.vaccine.2008.09.044] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2008] [Revised: 08/21/2008] [Accepted: 09/16/2008] [Indexed: 11/30/2022]
Abstract
The recent advances in molecular genetics, pathogenesis and immunology have provided an optimal framework for developing novel approaches in the rational design of vaccines effective against viral epizootic diseases. This paper reviews most of the viral-vector based antigen delivery systems (ADSs) recently developed for vaccine testing in veterinary species, including attenuated virus and DNA and RNA viral vectors. Besides their usefulness in vaccinology, these ADSs constitute invaluable tools to researchers for understanding the nature of protective responses in different species, opening the possibility of modulating or potentiating relevant immune mechanisms involved in protection.
Collapse
|
23
|
Farnós O, Fernández E, Chiong M, Parra F, Joglar M, Méndez L, Rodríguez E, Moya G, Rodríguez D, Lleonart R, González EM, Alonso A, Alfonso P, Suárez M, Rodríguez MP, Toledo JR. Biochemical and structural characterization of RHDV capsid protein variants produced in Pichia pastoris: Advantages for immunization strategies and vaccine implementation. Antiviral Res 2009; 81:25-36. [DOI: 10.1016/j.antiviral.2008.08.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2008] [Revised: 08/25/2008] [Accepted: 08/28/2008] [Indexed: 11/30/2022]
|
24
|
Review of companion animal viral diseases and immunoprophylaxis. Vaccine 2008; 27:491-504. [PMID: 19041354 PMCID: PMC7130499 DOI: 10.1016/j.vaccine.2008.11.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2008] [Accepted: 11/05/2008] [Indexed: 12/01/2022]
Abstract
In this article we review important established, newly emergent and potential viral diseases of cats, dogs and rabbits. Topics covered include virus epidemiology, disease pathogenesis, existing and prospective immunoprophylaxis against the viruses. For some feline viruses, notably the immunodeficiency virus, leukaemia virus and peritonitis virus, available vaccines are poorly efficacious but there are good prospects for this. A further challenge for the industry is likely to be due to viruses jumping species and the emergence of more virulent variants of established viruses resulting from mutations as has been the case for the canine parvovirus, coronaviruses and feline calicivirus.
Collapse
|
25
|
Adams MM, van Leeuwen BH, McFadden G, Kerr PJ. Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells. Vet Res 2008; 39:60. [PMID: 18778680 DOI: 10.1051/vetres:2008037] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2008] [Accepted: 09/04/2008] [Indexed: 11/14/2022] Open
Abstract
Deletion of the M063 gene from myxoma virus produces a virus that is unable to replicate in rabbit cells in vitro or in live rabbits but can be propagated in non-rabbit cell lines. A targeted M063 deletion mutant was constructed in the attenuated Uriarra strain of myxoma virus and the ability of this virus to act as a safe, non-transmissible vaccine against myxomatosis was tested in outbred laboratory rabbits. Immunization with the M063 deletion vaccine provided good short-term protection against lethal challenge with virulent myxoma virus. Long-term protection was similar to reported results with heterologous live virus, with some rabbits protected but others succumbing to challenge. Replication-deficient poxvirus vaccines, like the Modified Vaccinia Virus Ankara (MVA) in man and the myxoma virus vaccine described here in rabbits, are very attractive from a safety perspective. Seasonal boosting would be predicted to provide long-term protection. Targeted host-range gene deletions could have potential for rapid development of poxvirus vaccines in general.
Collapse
Affiliation(s)
- Mathew M Adams
- School of Biochemistry and Molecular Biology, College of Science, The Australian National University, Canberra, ACT 0200, Australia
| | | | | | | |
Collapse
|
26
|
Pignolet B, Boullier S, Gelfi J, Bozzetti M, Russo P, Foulon E, Meyer G, Delverdier M, Foucras G, Bertagnoli S. Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants. J Gen Virol 2008; 89:1371-1379. [PMID: 18474552 DOI: 10.1099/vir.0.83595-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Myxoma virus (MYXV), a leporide-specific poxvirus, represents an attractive candidate for the generation of safe and non-replicative vaccine vectors for other species. With the aim of developing new recombinant vaccines for ruminants, we evaluated the safety and the immunogenicity of recombinant MYXV in sheep. In vitro studies indicated that ovine primary fibroblasts were not permissive for MYXV and that infection of ovine peripheral blood mononuclear cells occurred at a low rate. Although non-specific activation significantly improved the susceptibility of lymphocytes, MYXV infection remained abortive. Histological and immunohistochemical examination at the inoculation sites revealed the development of an inflammatory process and allowed the detection of sparse infected cells in the dermis. In addition, inoculated sheep developed an antibody response directed against MYXV and the product of the transgene. Overall, these results provide the first line of evidence on the potential of MYXV as a viral vector for ruminants.
Collapse
Affiliation(s)
- Béatrice Pignolet
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Séverine Boullier
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Jacqueline Gelfi
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Marjorie Bozzetti
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Pierre Russo
- AFSSA LERPRA les Templiers, 105 route des Chappes, F-06902 Sophia Antipolis, France
| | - Eliane Foulon
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Gilles Meyer
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Maxence Delverdier
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Gilles Foucras
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| | - Stéphane Bertagnoli
- Université de Toulouse, ENVT, UMR 1225, F-31076 Toulouse, France.,INRA, UMR 1225, F-31076 Toulouse, France
| |
Collapse
|
27
|
Vaccination of free-living juvenile wild rabbits (Oryctolagus cuniculus) against myxomatosis improved their survival. Prev Vet Med 2008; 84:1-10. [DOI: 10.1016/j.prevetmed.2007.10.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2006] [Revised: 07/13/2007] [Accepted: 10/09/2007] [Indexed: 11/21/2022]
|
28
|
Pignolet B, Duteyrat JL, Allemandou A, Gelfi J, Foucras G, Bertagnoli S. In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains. Virol J 2007; 4:94. [PMID: 17900332 PMCID: PMC2045666 DOI: 10.1186/1743-422x-4-94] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2007] [Accepted: 09/27/2007] [Indexed: 11/10/2022] Open
Abstract
Myxoma virus (MYXV), a leporide-specific poxvirus, represents an attractive candidate for the generation of safe, non-replicative vaccine vector for non-host species. However, there is very little information concerning infection of non-laboratory animals species cells with MYXV. In this study, we investigated interactions between bovine cells and respectively a wild type strain (T1) and a vaccinal strain (SG33) of MYXV. We showed that bovine KOP-R, BT and MDBK cell lines do not support MYXV production. Electron microscopy observations of BT-infected cells revealed the low efficiency of viral entry and the production of defective virions. In addition, infection of bovine peripheral blood mononuclear cells (PBMC) occurred at a very low level, even following non-specific activation, and was always abortive. We did not observe significant differences between the wild type strain and the vaccinal strain of MYXV, indicating that SG33 could be used for new bovine vaccination strategies.
Collapse
Affiliation(s)
- Béatrice Pignolet
- Laboratory « Interactions Hôtes-Virus et Vaccinologie », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
| | - Jean-Luc Duteyrat
- Laboratory « Interactions Hôtes-Virus et Vaccinologie », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
- Centre de Microscopie Electronique Appliquée à la Biologie, Faculté de Médecine de Rangueil, 133 route de Narbonne, Toulouse, F-31062, France
| | - Aude Allemandou
- Laboratory « Interactions Hôtes-Virus et Vaccinologie », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
- Centre de Microscopie Electronique Appliquée à la Biologie, Faculté de Médecine de Rangueil, 133 route de Narbonne, Toulouse, F-31062, France
| | - Jacqueline Gelfi
- Laboratory « Interactions Hôtes-Virus et Vaccinologie », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
| | - Gilles Foucras
- laboratory « Résistome des ruminants », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
| | - Stéphane Bertagnoli
- Laboratory « Interactions Hôtes-Virus et Vaccinologie », UMR 1225 INRA-ENVT, Ecole Nationale Vétérinaire de Toulouse, 23 chemin des capelles, Toulouse F-31076, France
| |
Collapse
|
29
|
Pérez-Filgueira DM, Resino-Talaván P, Cubillos C, Angulo I, Barderas MG, Barcena J, Escribano JM. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 2007; 364:422-30. [PMID: 17434554 DOI: 10.1016/j.virol.2007.03.016] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2007] [Revised: 02/13/2007] [Accepted: 03/10/2007] [Indexed: 01/20/2023]
Abstract
Vaccine antigens against rabbit hemorrhagic disease virus (RHDV) are currently derived from inactivated RHDV obtained from livers of experimentally infected rabbits. Several RHDV-derived recombinant immunogens have been reported. However, their application in vaccines has been restricted due to their high production costs. In this paper, we describe the development of an inexpensive, safe, stable vaccine antigen for RHDV. A baculovirus expressing a recombinant RHDV capsid protein (VP60r) was used to infect Trichoplusia ni insect larvae. It reached an expression efficiency of 12.5% of total soluble protein, i.e. approximately 2 mg of VP60r per larva. Preservation of the antigenicity and immunogenicity of the VP60r was confirmed by immunological and immunization experiments. Lyophilized crude larvae extracts, containing VP60r, were stable, at room temperature, for at least 800 days. In all cases, rabbits immunized with a single dose of VP60r by the intramuscular route were protected against RHDV challenge. Doses used were as low as 2 microg of VP60r in the presence of adjuvant or 100 microg without one. Orally administered VP60r in the absence of an adjuvant gave no protection. The potential costs of an RHDV vaccine made using this technology would be reduced considerably compared with producing the same protein in insect cells maintained by fermentation. In conclusion, the larva expression system may provide a broad-based strategy for production of recombinant subunit antigens (insectigens) for human or animal medicines, especially when production costs restrain their use.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antibodies, Viral/biosynthesis
- Antigens, Viral/genetics
- Antigens, Viral/isolation & purification
- Baculoviridae/genetics
- Caliciviridae Infections/immunology
- Caliciviridae Infections/prevention & control
- Caliciviridae Infections/veterinary
- Costs and Cost Analysis
- Hemorrhagic Disease Virus, Rabbit/genetics
- Hemorrhagic Disease Virus, Rabbit/immunology
- Injections, Intramuscular
- Larva
- Moths
- Rabbits
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/economics
- Vaccines, Subunit/genetics
- Vaccines, Subunit/isolation & purification
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/economics
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/isolation & purification
- Viral Structural Proteins/genetics
- Viral Structural Proteins/immunology
- Viral Structural Proteins/isolation & purification
- Viral Vaccines/administration & dosage
- Viral Vaccines/economics
- Viral Vaccines/genetics
- Viral Vaccines/isolation & purification
Collapse
|
30
|
Angulo E, Bárcena J. Towards a unique and transmissible vaccine against myxomatosis and rabbit haemorrhagic disease for rabbit populations. WILDLIFE RESEARCH 2007. [DOI: 10.1071/wr06160] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Currently available vaccines against myxomatosis and rabbit hemorrhagic disease virus (RHDV) are not suited to immunise wild rabbit populations, as vaccines need to be delivered individually by conventional veterinary practices. As an alternative approach, research in Spain has focused on the development of a transmissible vaccine. A recombinant virus has been constructed based on a naturally attenuated myxoma virus (MV) field strain, expressing the RHDV capsid protein (VP60). Following inoculation of rabbits, the recombinant virus (MV-VP60) induced specific antibody responses against MV and RHDV, conferring protection against lethal challenges with both viruses. Furthermore, the recombinant MV-VP60 virus showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunisation of contact uninoculated animals. Efficacy and safety of the vaccine have been extensively evaluated under laboratory conditions and in a limited field trial. The development of the transmissible vaccine strategy and the steps being taken to obtain the marketing authorisation for the vaccine in the European Union are presented in this review.
Collapse
|
31
|
Duteyrat JL, Gelfi J, Bertagnoli S. Ultrastructural study of myxoma virus morphogenesis. Arch Virol 2006; 151:2161-80. [PMID: 16763732 DOI: 10.1007/s00705-006-0791-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2005] [Accepted: 04/26/2006] [Indexed: 10/24/2022]
Abstract
Poxviruses are among the largest and most complex viruses known. Vaccinia virus, the prototype of the family Poxviridae, has been studied much more than myxoma virus. The aim of this work was to have a better knowledge about myxoma virus morphogenesis. The characterization of the main stages of MV morphogenesis was achieved by ultrastructural and immunological analysis. Specific antibodies were raised against M022L and M071L, two envelope proteins of extracellular enveloped virus and intracellular mature virus, respectively. The main stages of assembly were similar to those seen with other poxviruses, and the duration of the whole replication cycle was estimated to be around 16 h, longer than what was described for vaccinia virus. Morphological changes of infected cells were associated with the development of long cellular projections and enlarged microvilli. Intracellular enveloped viruses are associated with the cytoskeleton to move through the cell. Unlike earlier studies, as many cell-associated enveloped viruses as intracellular enveloped viruses were observed in relation with specialized microvilli, although these structures were rarely noticed. Finally, an unusual spreading process was observed, which uses cytoplasmic corridors.
Collapse
Affiliation(s)
- J-L Duteyrat
- UMR 1225 Interactions Hôtes-Agents pathogènes, INRA/ENVT, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France
| | | | | |
Collapse
|
32
|
Farnós O, Boué O, Parra F, Martín-Alonso JM, Valdés O, Joglar M, Navea L, Naranjo P, Lleonart R. High-level expression and immunogenic properties of the recombinant rabbit hemorrhagic disease virus VP60 capsid protein obtained in Pichia pastoris. J Biotechnol 2005; 117:215-24. [PMID: 15862351 DOI: 10.1016/j.jbiotec.2005.01.013] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2004] [Revised: 01/18/2005] [Accepted: 01/29/2005] [Indexed: 11/23/2022]
Abstract
The VP60 capsid protein from rabbit hemorrhagic disease virus (RHDV) (Spanish isolate AST/89) was cloned and expressed in Pichia pastoris. The transformed yeast was grown at high cell density and an expression level of about 1.5 g VP60L(-1) culture was obtained. The protein was detected associated with the cell debris fraction of the recombinant yeast after mechanical disruption. It was purified by a simple method and was obtained N-glycosylated with purity of approximately 70% as deduced from densitometry scan analysis. The recombinant product was antigenically similar to the native capsid protein as determined with polyclonal antibodies obtained from rabbits vaccinated with VP60 protein purified from native virus. The immunogenicity of VP60 protein purified from P. pastoris was demonstrated by ELISA in a vaccination experiment conducted with two groups of rabbits subcutaneously immunized. Animals vaccinated with VP60 in Freund's incomplete adjuvant developed a significant (p<0.01) virus-specific antibody response while the group injected with placebo remained seronegative. Preliminary results showed that the antigen administered within the cell debris fraction of the transformed yeast protected rabbits immunized by the oral route against an intramuscular challenge with 100 LD50 (16,000 hemagglutination units) of homologous virus.
Collapse
Affiliation(s)
- Omar Farnós
- Animal Biotechnology Division, Center for Genetic Engineering and Biotechnology, P.O. Box 6162, CP 10600, Havana, Cuba.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Calvete C, Estrada R, Lucientes J, Osacar JJ, Villafuerte R. Effects of vaccination against viral haemorrhagic disease and myxomatosis on long-term mortality rates of European wild rabbits. Vet Rec 2004; 155:388-92. [PMID: 15499810 DOI: 10.1136/vr.155.13.388] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The effects of vaccination against myxomatosis and viral haemorrhagic disease (VHD) on long-term mortality rates in European rabbits (Oryctolagus cuniculus) were studied from 1993 to 1996 by radiotracking a free-living population of wild rabbits. During the three months after immunisation, unvaccinated young rabbits weighing between 180 and 600 g were 13.6 times more likely to die than vaccinated young rabbits. In adult rabbits, vaccination did not significantly decrease mortality, mainly owing to the high proportion of rabbits which had previously been exposed to the antigens of both diseases. Compared with adult rabbits with natural antibodies to VHD, rabbits without these antibodies were 5.2 times more likely to die of VHD during annual outbreaks.
Collapse
Affiliation(s)
- C Calvete
- Departamento de Patología Animal, Facultad de Veterinaria, Universidad de Zaragoza, c/Miguel Servet 177, 50013 Zaragoza, Spain
| | | | | | | | | |
Collapse
|
34
|
Bárcena J, Verdaguer N, Roca R, Morales M, Angulo I, Risco C, Carrascosa JL, Torres JM, Castón JR. The coat protein of Rabbit hemorrhagic disease virus contains a molecular switch at the N-terminal region facing the inner surface of the capsid. Virology 2004; 322:118-34. [PMID: 15063122 DOI: 10.1016/j.virol.2004.01.021] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2003] [Revised: 01/16/2004] [Accepted: 01/19/2004] [Indexed: 11/22/2022]
Abstract
To function adequately, many if not all proteins involved in macromolecular assemblies show conformational polymorphism as an intrinsic feature. This general strategy has been described for many essential cellular processes. Here we describe this structural polymorphism in a viral protein, the coat protein of Rabbit hemorrhagic disease virus (RHDV), which is required during virus capsid assembly. By combining genetic, structure modeling, and cryo-electron microscopy and image processing analysis, we have established the mechanism that allows RHDV coat protein to switch among quasi-equivalent conformational states to achieve the appropriate curvature for the formation of a closed shell. The RHDV capsid structure is based on a T = 3 lattice, containing 180 copies of identical subunits, similar to those of other caliciviruses. The quasi-equivalent interactions between the coat proteins are achieved by the N-terminal region of a subset of subunits, which faces the inner surface of the capsid shell. Mutant coat protein lacking this N-terminal sequence assembles into T = 1 capsids. Our results suggest that the polymorphism of the RHDV T = 3 capsid might bear resemblance to that of plant virus T = 3 capsids.
Collapse
Affiliation(s)
- Juan Bárcena
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Gu W, Holland M, Janssens P, Kerr P. Antibody response in the female rabbit reproductive tract to influenza haemagglutinin encoded by a recombinant myxoma virus. Virology 2003; 313:286-95. [PMID: 12951040 DOI: 10.1016/s0042-6822(03)00324-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The antibody response in serum and the reproductive tract of female rabbits to a model antigen, influenza virus haemagglutinin (HA), encoded by a recombinant myxoma virus was investigated. Strong and lasting IgG antibody responses to HA were induced in serum following intradermal, intranasal, and intravaginal immunisations. HA IgG was also detected in reproductive tract fluids but was only about 1% the titer of that in serum. HA IgA was not detected in serum of any infected groups and was occasionally detected in reproductive tract fluids at a low titer only after infections through mucosal sites. HA IgM was also detected only in some of the reproductive tract fluids at very low levels. Induction of ovulation did not change these patterns and B cell homing to the reproductive tract was not profound. In contrast, HA IgG and IgM titers in ovarian follicular fluids were comparable to that in serum. These data suggest that if this virus is used to deliver an immunocontraceptive vaccine that requires a high-level antibody response, the target antigen needs to be accessible to serum antibody or in the ovary.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/analysis
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/blood
- Contraception, Immunologic
- Female
- Follicular Fluid/immunology
- Genetic Vectors
- Genitalia, Female/immunology
- Hemagglutinin Glycoproteins, Influenza Virus/biosynthesis
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Immunity, Mucosal
- Immunization
- Immunoglobulin A, Secretory/analysis
- Immunoglobulin G/blood
- Immunoglobulin M/analysis
- Models, Animal
- Myxoma virus/genetics
- Myxoma virus/metabolism
- Orthomyxoviridae/immunology
- Ovulation
- Rabbits
- Recombinant Proteins/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Wenyi Gu
- Division of Biochemistry and Molecular Biology, the School of Life Science, The Australian National University, Canberra, Australia.
| | | | | | | |
Collapse
|
36
|
Abstract
European wild rabbits originated in southwestern Europe but have been introduced into many other countries world-wide, becoming serious pests in many instances. As a consequence of rabbits being regarded so differently, applied research for their management often has opposing goals, namely their conservation or their control. Furthermore, modern gene technology has led to the concept of using genetically modified myxoma viruses for rabbit management, again with quite contrary aims in mind. In this paper we explain the possible ecological and economic consequences of using these genetically modified viruses inappropriately and we consider whether national and international regulations are sufficient to prevent improper use. If international regulations are inadequate, molecular biologists and ecologists must consider the consequences of their research and advice beyond their own country to avoid unwanted impacts.
Collapse
Affiliation(s)
- E Angulo
- Estación Biológica de Doñana, Apdo 1056, E-41080 Sevilla, Spain.
| | | |
Collapse
|
37
|
McCabe VJ, Tarpey I, Spibey N. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine 2002; 20:2454-62. [PMID: 12057600 DOI: 10.1016/s0264-410x(02)00186-x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Myxoma virus, a member of the Poxviridae family (genus Leporipoxvirus) is the agent responsible for myxomatosis in the European rabbit. Recombinant myxoma viruses expressing the capsid gene of an F9 strain of feline calicivirus (FCV) were constructed from an apathogenic, laboratory attenuated, isolate of myxoma virus. The FCV capsid genes were recombined into the myxoma growth factor (MGF) locus of the myxoma genome and expressed from synthetic poxvirus promoters. Myxoma virus is unable to replicate productively in feline cells in vitro, however, cells infected with recombinant viruses do express the heterologous antigens from both late and early/late synthetic promoters. Cats immunised with myxoma-FCV recombinant virus generated high levels of serum neutralising antibody and were protected from disease on subsequent challenge with virulent FCV. Furthermore, there was no evidence of transmission of myxoma-FCV recombinant virus from vaccinated to non-vaccinated cats. These results demonstrate the potential of myxoma virus as a safe vaccine vector for use in non-lepori species and in particular the cat.
Collapse
Affiliation(s)
- Victoria J McCabe
- Department of Molecular Studies, Intervet UK Ltd., The Elms, Houghton, Huntingdon, Cambridge, UK
| | | | | |
Collapse
|
38
|
Guerin JL, Gelfi J, Boullier S, Delverdier M, Bellanger FA, Bertagnoli S, Drexler I, Sutter G, Messud-Petit F. Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins. J Virol 2002; 76:2912-23. [PMID: 11861858 PMCID: PMC135958 DOI: 10.1128/jvi.76.6.2912-2923.2002] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Down-modulation of major histocompatibility class I (MHC-I) molecules is a viral strategy for survival in the host. Myxoma virus, a member of the Poxviridae family responsible for rabbit myxomatosis, can down-modulate the expression of MHC-I molecules, but the viral factor(s) has not been described. We cloned and characterized a gene coding for an endoplasmic reticulum (ER)-resident protein containing an atypical zinc finger and two transmembrane domains, which we called myxoma virus leukemia-associated protein (MV-LAP). MV-LAP down-regulated surface MHC-I and Fas-CD95 molecules upon transfection; the mechanism probably involves an exacerbation of endocytosis and was lost when the ER retention signal was removed. In addition, the lytic activity of MHC-I-restricted antigen-specific cytolytic T lymphocytes (CTL) against myxoma virus-infected antigen-presenting target cells was significantly reduced, revealing a strong correlation between MHC-I down-regulation by MV-LAP and CTL killing in vitro. In vivo experiments with a knockout virus showed that MV-LAP is a virulence factor, potentially involved in the immunosuppression characteristic of myxomatosis. Data bank analysis revealed that MV-LAP has homologs in herpesviruses and other poxviruses. We propose the name "scrapins" to define a new group of ER-resident surface cellular receptor abductor proteins. The down-regulation of cell surface molecules by scrapins probably helps protect infected cells during viral infections.
Collapse
Affiliation(s)
- Jean-Luc Guerin
- UMR 960 Microbiologie Moléculaire, Institut National de la Recherche Agronomique and Ecole Nationale Vétérinaire, 31076 Toulouse, France
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Torres JM, Sánchez C, Ramírez MA, Morales M, Bárcena J, Ferrer J, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine 2001; 19:4536-43. [PMID: 11483281 DOI: 10.1016/s0264-410x(01)00184-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
As a novel approach for immunisation of wild rabbits, we have recently developed a transmissible vaccine against myxomatosis and rabbit hemorrhagic disease (RHD) based on a recombinant myxoma virus (MV) expressing the RHDV capsid protein [J. Virol. 74 (2000) 1114]. The efficacy and safety of the vaccine have been extensively evaluated under laboratory conditions. In this study, we report the first limited field trial of the candidate vaccine that was undertaken in an island of 34 Has containing a population of around 300 rabbits. Following administration by the subcutaneous route to 76 rabbits, the vaccine induced specific antibody responses against both myxomatosis and RHDV in all the inoculated rabbits. Furthermore, the recombinant virus exhibited a limited horizontal transmission capacity, promoting seroconversion of around 50% of the uninoculated rabbit population. No evidence of undesirable effects due to the recombinant virus field release was detected.
Collapse
Affiliation(s)
- J M Torres
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, 28130, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Fernández-Fernández MR, Mouriño M, Rivera J, Rodríguez F, Plana-Durán J, García JA. Protection of rabbits against rabbit hemorrhagic disease virus by immunization with the VP60 protein expressed in plants with a potyvirus-based vector. Virology 2001; 280:283-91. [PMID: 11162842 DOI: 10.1006/viro.2000.0762] [Citation(s) in RCA: 103] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A new plum pox potyvirus (PPV)-based vector has been constructed for the expression of full-length individual foreign proteins. The foreign sequences are cloned between the NIb replicase and capsid protein (CP) cistrons. The heterologous protein is split from the rest of the potyviral polyprotein by cleavage at the site that originally separated the NIb and CP proteins and at an additional NIa protease recognition site engineered at its amino-terminal end. This vector (PPV-NK) has been used to clone different genes, engendering stable chimeras with practical applications. We have constructed a chimera expressing high levels of jellyfish green fluorescent protein, which can be very useful for the study of PPV molecular biology. The VP60 structural protein of rabbit hemorrhagic disease virus (RHDV) was also successfully expressed by making use of the PPV-NK vector. Inoculation of extracts from VP60-expressing plants induced a remarkable immune response against RHDV in rabbits, its natural host. Moreover, these animals were protected against a lethal challenge with RHDV.
Collapse
Affiliation(s)
- M R Fernández-Fernández
- Centro Nacional de Biotecnología-CSIC, Campus de la Universidad Autónoma de Madrid, 28049 Madrid, Spain
| | | | | | | | | | | |
Collapse
|
41
|
Torres JM, Ramírez MA, Morales M, Bárcena J, Vázquez B, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM. Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease. Vaccine 2000; 19:174-82. [PMID: 10930670 PMCID: PMC7125741 DOI: 10.1016/s0264-410x(00)00183-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114-23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.
Collapse
Affiliation(s)
- J M Torres
- Centro de Investigación en Sanidad Animal (CISA-INIA), Valdemos, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Perkins HD, van Leeuwen BH, Hardy CM, Kerr PJ. The complete cDNA sequences of IL-2, IL-4, IL-6 AND IL-10 from the European rabbit (Oryctolagus cuniculus). Cytokine 2000; 12:555-65. [PMID: 10843729 DOI: 10.1006/cyto.1999.0658] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The cDNAs for four rabbit cytokine genes [interleukin 2 (IL-2), IL-4, IL-6 and IL-10] have been cloned from primary lymphocytes by polymerase chain reaction (PCR) methods. IL-2 and IL-10 are both highly conserved between rabbit and other species. IL-4 and IL-6 are less strongly conserved, at both nucleotide and amino acid levels, and exhibit structural differences. An extension of the coding region of rabbit IL-6 relative to all other reported IL-6 genes results from a mutation in the usual stop codon which allows translation to continue for a further 27 amino acids. Analysis of IL-6 from four other lagomorph species suggests that this mutation is specific to the European rabbit. Sequence and structural differences of IL-4 and IL-6, while presumably not altering function, may render them highly species-specific. Several alternatively spliced variants of IL-2 and IL-4 are also reported.
Collapse
Affiliation(s)
- H D Perkins
- Division of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT, 0200, Australia.
| | | | | | | |
Collapse
|
43
|
|
44
|
Sánchez MS, Arnold J, Asmussen MA. Symbiont survival and host-symbiont disequilibria under differential vertical transmission. Genetics 2000; 154:1347-65. [PMID: 10757775 PMCID: PMC1460980 DOI: 10.1093/genetics/154.3.1347] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Interspecific genetic interactions in host-symbiont systems raise intriguing coevolutionary questions and may influence the effectiveness of public health and management policies. Here we present an analytical and numerical investigation of the effects of host genetic heterogeneity in the rate of vertical transmission of a symbiont. We consider the baseline case with a monomorphic symbiont and a single diallelic locus in its diploid host, where vertical transmission is the sole force. Our analysis introduces interspecific disequilibria to quantify nonrandom associations between host genotypes and alleles and symbiont presence/absence. The transient and equilibrium behavior is examined in simulations with randomly generated initial conditions and transmission parameters. Compared to the case where vertical transmission rates are uniform across host genotypes, differential transmission (i) increases average symbiont survival from 50% to almost 60%, (ii) dramatically reduces the minimum average transmission rate for symbiont survival from 0.5 to 0.008, and (iii) readily creates permanent host-symbiont disequilibria de novo, whereas uniform transmission can neither create nor maintain such associations. On average, heterozygotes are slightly more likely to carry and maintain the symbiont in the population and are more randomly associated with the symbiont. Results show that simple evolutionary forces can create substantial nonrandom associations between two species.
Collapse
Affiliation(s)
- M S Sánchez
- Department of Genetics, University of Georgia, Athens, Georgia 30602, USA.
| | | | | |
Collapse
|
45
|
Marlier D, Mainil J, Boucraut-Baralon C, Linden A, Vindevogel H. The efficacy of two vaccination schemes against experimental infection with a virulent amyxomatous or a virulent nodular myxoma virus strain. J Comp Pathol 2000; 122:115-22. [PMID: 10684680 DOI: 10.1053/jcpa.1999.0346] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Two types of myxomatosis vaccine are available commercially, namely, vaccine prepared from the Shope fibroma virus (SFV) and that prepared from an attenuated myxoma virus (MV) strain, e.gSG33. An experiment was designed to compare two vaccination schemes for their ability to protect rabbits against challenge with either a virulent amyxomatous MV strain or a virulent nodular MV strain. Apart from a difference in the cutaneous expression of the disease, the two challenge strains resembled each other in respect of mortality rate, naso-conjunctival shedding of virus, and tissue infection. Vaccination with SFV alone failed to prevent clinical signs, naso-conjunctival shedding or tissue infection. Vaccination with SFV followed by a booster inoculation with SG33 protected rabbits against the development of clinical signs and significantly reduced both viral shedding in naso-conjunctival exudates and viral infection of eyelids, lungs and testes; virus was, however, isolated from testes of some surviving animals.
Collapse
Affiliation(s)
- D Marlier
- Department of Bird and Rabbit Medicine, Faculty of Veterinary Medicine, University of Liège, Bld de Colonster 20,Bat B42, Sart-Tilman, Liège, B4000, Belgium
| | | | | | | | | |
Collapse
|
46
|
Bárcena J, Morales M, Vázquez B, Boga JA, Parra F, Lucientes J, Pagès-Manté A, Sánchez-Vizcaíno JM, Blasco R, Torres JM. Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus. J Virol 2000; 74:1114-23. [PMID: 10627521 PMCID: PMC111445 DOI: 10.1128/jvi.74.3.1114-1123.2000] [Citation(s) in RCA: 68] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/1999] [Accepted: 11/01/1999] [Indexed: 11/20/2022] Open
Abstract
We have developed a new strategy for immunization of wild rabbit populations against myxomatosis and rabbit hemorrhagic disease (RHD) that uses recombinant viruses based on a naturally attenuated field strain of myxoma virus (MV). The recombinant viruses expressed the RHDV major capsid protein (VP60) including a linear epitope tag from the transmissible gastroenteritis virus (TGEV) nucleoprotein. Following inoculation, the recombinant viruses induced specific antibody responses against MV, RHDV, and the TGEV tag. Immunization of wild rabbits by the subcutaneous and oral routes conferred protection against virulent RHDV and MV challenges. The recombinant viruses showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunization of contact uninoculated animals.
Collapse
Affiliation(s)
- J Bárcena
- Centro de Investigación en Sanidad Animal, Valdeolmos, 28130 Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Marlier D, Cassart D, Boucraut-Baralon C, Coignoul F, Vindevogel H. Experimental infection of specific pathogen-free New Zealand White rabbits with five strains of amyxomatous myxoma virus. J Comp Pathol 1999; 121:369-84. [PMID: 10542126 DOI: 10.1053/jcpa.1999.0335] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Myxomatosis is a specific disease of the European rabbit (Oryctolagus cuniculus) due to a virus belonging to the genus Leporipoxvirus. Forty-seven years after its deliberate introduction into Europe, the clinical aspects and the epizootiology of myxomatosis have changed. Two forms (nodular and amyxomatous) of the disease have been identified to date. A comparative study was made of the clinical signs, pathogenesis and gross lesions observed in male specific pathogen-free New Zealand White rabbits inoculated with five strains of amyxomatous myxoma virus. All five strains induced the characteristic amyxomatous myxomatosis clinical syndrome with clinical signs that differed only in intensity. The varying clinical intensity, together with the results of virological examination question the virulence of at least three of the five strains. Genomic analysis confirmed that the five strains came from the Lausanne strain introduced in 1952 in France and not from an unnoticed introduction of a Californian strain of myxoma virus. No link was found between the amyxomatous myxoma virus strains and the SG33 vaccine strain. 1999 Harcourt Publishers Ltd.
Collapse
Affiliation(s)
- D Marlier
- Faculté de Médecine Vétérinaire, Université de Liège, Bld de Colonster 20, Bat B42, Sart-Tilman, 4000 Liège, Belgique
| | | | | | | | | |
Collapse
|
48
|
Castañón S, Marín MS, Martín-Alonso JM, Boga JA, Casais R, Humara JM, Ordás RJ, Parra F. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol 1999; 73:4452-5. [PMID: 10196345 PMCID: PMC104230 DOI: 10.1128/jvi.73.5.4452-4455.1999] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The major structural protein VP60 of rabbit hemorrhagic disease virus (RHDV) has been produced in transgenic potato plants under the control of a cauliflower mosaic virus 35S promoter or a modified 35S promoter that included two copies of a strong transcriptional enhancer. Both types of promoters allowed the production of specific mRNAs and detectable levels of recombinant VP60, which were higher for the constructs carrying the modified 35S promoter. Rabbits immunized with leaf extracts from plants carrying this modified 35S promoter showed high anti-VP60 antibody titers and were fully protected against the hemorrhagic disease.
Collapse
Affiliation(s)
- S Castañón
- Departamento de Biología de Organismos y Sistemas, Instituto Universitario de Biotecnología de Asturias (CSIC), Universidad de Oviedo, 33006 Oviedo, Spain
| | | | | | | | | | | | | | | |
Collapse
|